Agreed, a good announcement, seems like the first actual...

Agreed, a good announcement, seems like the first actual business announcement – of a non-quarterly /Medivet or formal reporting nature we’ve had, in sometime!

The expansion of product offerings in key areas such as infection prevention using established products that already have the associated regulatory approval and a proven track record are perfect for MLA. These can be immediately added to the sales team's range of offerings and don't have the cost and time barriers of developing the products in-house.

I personally feel like MLA is at ground zero, a costly lesson was learnt (largely the fault of an over exuberant previous management team) and now steps are being made to grow sustainably into a large human medical consumables company and there is potential to become a market leader in the Australia/NZ region. Growth and expansion has the potential to be self-funded and all the tools and planning seem to now be in place to accommodate this growth. Whilst I’m concerned with the SP at the moment, I believe in the company and think that a couple ‘clean’ quarters of growth will start to see some sustainable SP appreciation.


GLTA, DYOR, IMO etc....